Zhang C, Dong HK, Gao JM, Zeng QQ, Qiu JT, Wang JJ. Advances in the diagnosis and treatment of MET-variant digestive tract tumors. World J Gastrointest Oncol 2024; 16(11): 4338-4353 [PMID: 39554732 DOI: 10.4251/wjgo.v16.i11.4338]
Corresponding Author of This Article
Jia-Jia Wang, PhD, Doctor, Ultrasound of Medicine Department, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Shushan District, Hefei 230601, Anhui Province, China. ahwangjiajia@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chen Zhang, The First Department of Radiation Oncology, Lu’an Hospital of Traditional Chinese Medicine of Anhui Province, Lu’an 237000, Anhui Province, China
Hu-Ke Dong, The Fourth Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China
Jian-Ming Gao, The First Department of Oncology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230000, Anhui Province, China
Qi-Qi Zeng, Department of Gastroenterology, Nanjing University Affiliated Gulou Hospital, Nanjing 210008, Jiangsu Province, China
Jiang-Tao Qiu, Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, Beijing 100084, China
Jia-Jia Wang, Ultrasound of Medicine Department, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Co-first authors: Chen Zhang and Hu-Ke Dong.
Author contributions: Zhang C and Dong HK wrote the manuscript, they contributed equally to this study, and they are the co-first authors of this manuscript; Gao JM, Zeng QQ, and Qiu JT collected the data; Wang JJ guided the study. All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Supported by2023 Anhui Province Clinical Medical Research Transformation Project, No. 202304295107020016.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Jia Wang, PhD, Doctor, Ultrasound of Medicine Department, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Shushan District, Hefei 230601, Anhui Province, China. ahwangjiajia@163.com
Received: July 8, 2024 Revised: August 24, 2024 Accepted: September 10, 2024 Published online: November 15, 2024 Processing time: 109 Days and 4.5 Hours
Abstract
The receptor tyrosine kinase encoded by the MET gene plays an important role in various cellular processes such as growth, survival, migration and angiogenesis, and its abnormal activation is closely related to the occurrence and development of various tumors. This article reviews the recent advances in diagnosis and treatment of MET-variant digestive tract tumors. In terms of diagnosis, the application of next-generation sequencing technology and liquid biopsy technology makes the detection of MET variants more accurate and efficient, providing a reliable basis for individualized treatment. In terms of treatment, MET inhibitors such as crizotinib and cabotinib have shown good efficacy in clinical trials. In addition, the combination of immunotherapy and MET inhibitors also demonstrated potential synergies, further improving the therapeutic effect. However, the complexity and heterogeneity of drug resistance mechanisms are still one of the difficulties in current research. In the future, it is necessary to further deepen the understanding of the mechanism of MET variation and explore new combination treatment strategies to improve the overall survival rate and quality of life of patients. The diagnosis and treatment of MET-variant digestive tract tumors are moving towards precision and individualization, and have broad application prospects.
Core Tip: Our study reviews the progress in the use of MET variation in the diagnosis and treatment of digestive tract tumors and discusses the molecular mechanism of MET variation and its role in the genesis and development of digestive tract tumors. The analysis focused on the potential of MET variants as diagnostic markers and therapeutic targets, covering the latest research results and clinical trial data for MET-based targeted therapies. This paper also summarizes the current challenges and future research directions, aiming to provide new ideas and references for improving the diagnostic accuracy and treatment effectiveness of MET-variant digestive tract tumors.
